The DTNB Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the extensively characterized HeLa human cervical adenocarcinoma epithelial cell line. These cells carry a targeted disruption of the DTNB gene, which encodes beta-dystrobrevin, a key cytoplasmic component of the dystrophin-associated glycoprotein complex (DAPC). By eliminating dystrobrevin expression, this product provides researchers with a versatile loss-of-function model to investigate the roles of the DAPC in epithelial cell biology, with particular relevance to cancer biology and cytoskeletal organization.
The parental HeLa cell line, established from a cervical carcinoma, is one of the most widely employed models in biomedical research owing to its unlimited proliferative capacity and ease of genetic manipulation. As adherent epithelial cells, HeLa cells are optimally suited for studies of cell adhesion, migration, and invasion??processes that are intimately linked to the cytoskeleton and cell-matrix interactions. This well-characterized background ensures high reproducibility and allows seamless integration of the knockout cells into established experimental workflows for probing dystrobrevin function in a transformed epithelial context.
Beta-dystrobrevin functions as an organizational hub within the DAPC, forming direct associations with dystrophin, syntrophin, and the sarcoglycan complex, while also linking to the actin cytoskeleton and the transmembrane dystroglycan complex. Through these interactions, it contributes to membrane stability and mechanotransduction. DTNB also serves as a scaffold for signaling molecules, notably neuronal nitric oxide synthase (nNOS), placing it at the intersection of structural and signaling pathways. Upstream regulators include mechanical stress and integrin-mediated adhesion signals, while myogenic transcription factors such as MYOD1 can modulate its expression, though their influence in epithelial cells may vary. Downstream, dystrobrevin impacts dystrophin stabilization and actin cytoskeletal remodeling, influencing cell shape and motility.
In the HeLa cell model, disruption of DTNB enables a focused analysis of DAPC functions outside of muscle tissues. Because HeLa cells are epithelial in origin, the knockout provides a unique system to study dystrobrevin??s contributions to cancer-relevant phenotypes such as anchorage-independent growth, directional migration, and cell-extracellular matrix adhesion. The polyclonal nature of the knockout population captures a spectrum of gene editing events, which can better represent the genetic diversity encountered in tumor cell populations and is advantageous for unbiased functional screens and drug testing.
This knockout product is tailored for a range of molecular and cellular assays, including western blotting and immunofluorescence for verifying loss of dystrobrevin and assessing its binding partners?? localization, cell adhesion and wound healing assays to quantify migratory behavior, co-immunoprecipitation for mapping altered protein complexes, and RNA-sequencing to reveal transcriptomic changes. It also supports drug screening campaigns for compounds that modulate the DAPC in muscular dystrophy research. For technical specifications and ordering details, please contact Ascent Research.
